"Hirudins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
| Descriptor ID |
D006629
|
| MeSH Number(s) |
D12.644.861.060.875 D12.776.872.060.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hirudins".
Below are MeSH descriptors whose meaning is more specific than "Hirudins".
This graph shows the total number of publications written about "Hirudins" by people in this website by year, and whether "Hirudins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 3 | 0 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hirudins" by people in Profiles.
-
Bivalirudin dosing during prolonged intermittent renal replacement therapy: a case report. J Thromb Thrombolysis. 2021 Jul; 52(1):345-349.
-
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar; 8(3):424-433.
-
Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors. Am J Health Syst Pharm. 2012 Nov 15; 69(22):1993-8.
-
Comparison of percutaneous coronary intervention safety before and during the establishment of a transradial program at a teaching hospital. Am J Cardiol. 2012 Apr 15; 109(8):1154-9.
-
Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 2011 Apr 01; 77(5):671-9.
-
Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revasc Med. 2009 Jul-Sep; 10(3):156-61.
-
Impact of bivalirudin use on outcomes in nonagenarians undergoing percutaneous coronary intervention. J Interv Cardiol. 2009 Feb; 22(1):61-7.
-
Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock. Am J Cardiol. 2008 Aug 01; 102(3):287-91.
-
Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Am J Cardiol. 2008 Jul 15; 102(2):160-4.
-
Adjunct thrombus aspiration reduces mortality in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction with high-risk angiographic characteristics. Am J Cardiol. 2008 Feb 15; 101(4):452-6.